Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIN001 in non-hospitalized COVID-19
NCT05659459Phase 2Terminated
- Sponsor
- Curatis
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of pamapimod in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Curatis. Primary endpoint: COVID-19 symptoms evaluation at 28 days. Started Aug 2022; status: terminated.
02
Drugs
pamapimod
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05659459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659459.